Table 1.
All patients | RAD | ART | SRT | P-value | |
---|---|---|---|---|---|
Patients (n) | 110 | 37 | 38 | 35 | |
Age (years) | |||||
Median | 67 | 68 | 63 | 67 | |
Range | 47–83 | 50–83 | 47–77 | 57–76 | 0.004 |
T-stage | |||||
T1–T2 | 38 | 19 | 7 | 12 | |
T3–T4 | 72 | 18 | 31 | 23 | 0.007 |
i-PSA | |||||
<10 | 46 | 10 | 16 | 20 | |
10–20 | 33 | 10 | 12 | 11 | 0.028 |
>20 | 31 | 17 | 10 | 4 | |
GS | |||||
2–6 | 11 | 5 | 2 | 4 | |
7 | 55 | 14 | 24 | 17 | 0.335 |
8–10 | 44 | 18 | 12 | 14 | |
N | |||||
N0 | 64 | 27 | 14 | 23 | |
N1 | 26 | 10 | 10 | 6 | <0.001 |
Nx | 20 | 0 | 14 | 6 | |
Risk | |||||
0 < r < 15 | 22 | 5 | 7 | 10 | |
15 ≤ r <30 | 54 | 15 | 19 | 20 | 0.064 |
30 ≤ r | 34 | 17 | 12 | 5 |
RAD, radical radiotherapy; ART, adjuvant radiotherapy; SRT, salvage radiotherapy; i-PSA, initial prostate-specific antigen; GS, Gleason score.